Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.
Also called NCT04166331
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 136 participants
- Sponsor
- University Hospital, Limoges
- Registry
-
NCT04166331
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT04166331. Randomized; triple masking; primary purpose treatment. Start 2020-09-20 (actual); primary completion 2025-07-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
- Acronym
- ADAPT
- Condition
- Sepsis
- Condition
- Cardiomyopathies
- Condition
- Hypoperfusion
- Condition
- Left Ventricular Systolic Dysfunction
- Intervention (Drug)
- Placebos
- Intervention (Drug)
- Dobutamine
- Lead sponsor
- University Hospital, Limoges
- Collaborator
- Centre d'Investigation Clinique 1415
Record details
- Record id
cardio:ct-nct04166331- Content hash
08b9d02a1c1d48e3496a38a203f5dd277bc862f1215a9966f222c7912282c3f0